Anzeige
Mehr »
Login
Sonntag, 06.04.2025 Börsentäglich über 12.000 News von 688 internationalen Medien
Nach sensationellem Forschungsdurchbruch! Welche Aktie am Montag outperformen könnte...
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
133 Leser
Artikel bewerten:
(0)

Cord Blood America Management Team to Appear on National VoiceAmerica Radio Network

Finanznachrichten News

LAS VEGAS, Oct. 21 /PRNewswire/ -- Cord Blood America, Inc. (http://www.cordblood-america.com/) (BULLETIN BOARD: CBAI) , the umbilical cord blood stem cell preservation company focused on bringing the life-saving potential of stem cells to families nationwide and internationally, is pleased to announce that Chairman, CEO and co-founder Matthew Schissler and Dr. Geoffrey O'Neill, Vice President, Operations, will appear for one hour live on "Go Rogue & Get Rich" on The VoiceAmerica Radio Network.

Both Mr. Schissler and Dr. O'Neill will first describe the cord blood collection, process and storage procedure, and take questions about cord blood stem cells, including processing and storage, from the audience during the live international radio show at 2 p.m. Pacific, 5 p.m. Eastern on Monday, October 25 on the VoiceAmerica.com Business Channel (Go Rogue & Get Rich!) http://www.voiceamerica.com/.

"We are honored that Kevin asked us to be on the show. We recognize his show is geared towards building businesses. Any opportunity to preach the cord blood gospel is welcome by CBAI," Mr. Schissler said.

Kevin Lehmann, who hosts the program, is well known for his business acumen and advocacy for entrepreneurship and free enterprise. He successfully launched the largest lead generation and sales and marketing training company in Network Marketing history, helping to revolutionize the sector with a high-tech/high-touch philosophy.

Mr. Schissler co-founded Cord Blood America, Inc. in 2003 with the vision of bringing the life-saving potential of stem cells to families in the U.S. and worldwide. He has positioned the company to focus on strategic organic growth, accretive acquisitions and diversifying into new, undiscovered stem cell processing and storage opportunities.

Dr. O'Neill, who has 25 years experience in the stem cell industry, has published 78 papers on the sector. He was the recipient of the prestigious Jean Julliard Prize for Research from the International Society of Blood Transfusion and the International Society of Hematology.

"We are looking forward to this opportunity to tell a national audience about the accomplishments and future plans for Cord Blood America, which now has an international presence, with affiliations in China, South America and throughout Europe," Mr. Schissler said.

About Cord Blood America

Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/. For investor information, visit http://www.cordblood-america.com/.

CONTACT: Paul Knopick E & E Communications 949/707-5365 pknopick@eandecommunications.com

Cord Blood America, Inc.

CONTACT: Paul Knopick of E & E Communications, +1-949-707-5365,
pknopick@eandecommunications.com, for Cord Blood America, Inc.

Web Site: http://www.cordblood-america.com/
http://www.corcell.com/

© 2010 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.